

Major Depressive Disorder in the Era of Socialisolation: Current Pharmacotherapeutic Strategies and the Psychosocial Impact of Loneliness

¹ G. Sravani, ² C. Renuka tejaswini, ³ M. Janaki, ⁴ S. Ashraf begam, ⁵ T. Sai Sharvani

Student, Doctor of Pharmacy, Dr. K.V. Subba Reddy Institute of Pharmacy, Kurnool.

Associate Professor, Department of Pharmacy practice, Dr.K.VSubba Reddy Institute of Pharmacy, Kurnool.

Student, Doctor of Pharmacy, Dr. K.V. Subba Reddy Institute of Pharmacy, Kurnool.

Student, Doctor of Pharmacy, Dr. K.V. Subba Reddy Institute of Pharmacy, Kurnool

Student, Doctor of Pharmacy, Dr. K.V. Subba Reddy Institute of Pharmacy, Kurnool

Date of Submission: 05-03-2026

Date of Acceptance: 15-03-2026

ABSTRACT

Major depressive disorder (MDD) remains a leading contributor to global disability, with complex and heterogeneous etiologies that include biological, psychological, and social determinants. Recent ten years have seen rising attention to social isolation and loneliness distinct but interacting constructs that increase easily hurt, harmed, or attacked, whether physically, emotionally, or financially to MDD, worsen course and prognosis, and complicate treatment. This narrative review synthesizes existing or happening in the same time period relating to concepts and clinical literature on the psychobiological links between social isolation/loneliness and MDD, summarizes current pharmacotherapeutic strategies and reviews how pharmacotherapy should be integrated with psychosocial and community interventions to address loneliness-driven depression. We discuss monitoring, safety, and adherence issues that are amplified by isolation, special population considerations, and public-health implications, and conclude by proposing practical clinical recommendations and research priorities. Clinicians and policymakers should adopt integrated, person-centered approaches that combine evidence-based medication with targeted psychosocial and community-level interventions to reduce both symptom burden and the social determinants that sustain it.

KEYWORDS

Major depressive disorder, loneliness, social isolation, antidepressants, ketamine, augmentation, behavioral activation, social prescribing

I. INTRODUCTION

Major depressive disorder (MDD) is characterized by persistent low mood, weaker interest or pleasure, cognitive impairments, sleep and appetite disturbances, and functional decline. Despite the availability of effective pharmacotherapies and psychotherapies, many patients experience incomplete disappearance, the signs and symptoms of a disease after a period of improvement, or chronicity. Being closely joined is a fundamental human need, when not satisfied, subjective loneliness and objective social isolation have independent and cooperative effects on mental health. Structural social changes, technological changes in communication, and episodic social responses have made loneliness and isolation central concerns for clinicians and public health practitioners. Understanding how these social states modify risk, presentation, and treatment response in MDD is essential for effective, equitable care. This review unified whole current evidence on how social isolation and loneliness influence the pathophysiology and clinical course of MDD, outlines up-to-date pharmacotherapeutic strategies with attention to challenges posed by isolation, and highlights the imperative to combine medication with psychosocial and community-level interventions. The review targets clinicians, researchers, and policymakers seeking practical guidance and research directions

II. MATERIALS AND METHODS

A narrative review approach was used. Relevant articles were searched in PubMed, Scopus, Web of Science, and Google Scholar using the keywords: Major Depressive Disorder, pharmacotherapy, social isolation, and loneliness.

Studies published in English from 2010 to 2025 were considered. Only peer-reviewed research papers, clinical studies, and review articles related to depression treatment and the impact of social isolation were included. Non-relevant and non-scientific sources were excluded. The selected studies were reviewed, compared, and summarized to present current evidence.

III. RESULTS

The findings show that current antidepressant therapies (such as SSRIs, SNRIs, atypical antidepressants, and combination therapy) are effective in reducing depressive symptoms, but their success varies among individuals. The review also indicates that social isolation and loneliness increase the risk and severity of major depressive disorder, leading to poorer treatment outcomes. Patients with strong social support respond better to pharmacotherapy and show reduced relapse rates compared to those who are socially isolated.

IV. DISCUSSION

The present review highlights that Major Depressive Disorder is influenced by both biological and psychosocial factors. While current pharmacotherapeutic strategies such as SSRIs, SNRIs, and atypical antidepressants remain effective first-line treatments, their outcomes vary based on individual response and underlying social conditions. The findings emphasize that loneliness and social isolation act as significant contributors to the onset and progression of depression, worsening symptom severity and reducing treatment effectiveness.

Furthermore, patients with limited social interaction often experience reduced emotional resilience and lower adherence to treatment. This indicates that pharmacological treatment alone may not be sufficient for optimal recovery. Integrating social and psychological support, counseling, and community-based interaction can enhance therapeutic outcomes. Therefore, a combined approach that addresses both neurochemical imbalance and social well-being may provide a more comprehensive management strategy for MDD.

V. CONCLUSION

Loneliness and social isolation are potent, modifiable contributors to the burden of major depressive disorder. Pharmacotherapy remains essential, but its effectiveness is enhanced often decisively so when combined with psychosocial,

digital, and community-based interventions that specifically target social disconnectedness. Rapid-acting treatments expand acute options, particularly for severely ill or suicidal patients, but require integration with long-term strategies. Addressing MDD in the era of social isolation demands multidisciplinary clinical approaches and public-health investments to rebuild social connectedness, reduce structural barriers, and bring evidence-based treatments to those most at risk.

VI. ACKNOWLEDGMENT

The author sincerely acknowledges the guidance, encouragement, and support provided by faculty members and colleagues during the preparation of this review article. Special thanks to my institution for providing access to research resources and literature that contributed to the successful completion of this work. The author also expresses gratitude to family and friends for their continuous motivation and understanding throughout the writing process.

REFERENCES

- [1]. World Health Organization. Depression and other common mental disorders: global health estimates. Geneva: WHO; 2017.
- [2]. James SL, Abate D, Abate KH, et al. Global burden of disease 2017. *Lancet*. 2018;392(10159):1789–1858.
- [3]. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington (DC): APA; 2013.
- [4]. Malhi GS, Mann JJ. Depression. *Lancet*. 2018;392(10161):2299–2312.
- [5]. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressants. *Lancet*. 2018;391(10128):1357–1366.
- [6]. Gelenberg AJ. The current state of antidepressant therapy. *J Clin Psychiatry*. 2010;71(12):e26.
- [7]. Rush AJ, Trivedi MH, Wisniewski SR, et al. Outcomes from the STAR*D trial. *Am J Psychiatry*. 2006;163(11):1905–1917.
- [8]. Marcus M, Yasamy MT, van Ommeren M, et al. Depression: A global public health concern. WHO; 2012.
- [9]. Kessler RC, Bromet EJ. The epidemiology of depression. *Annu Rev Public Health*. 2013;34:119–138.

- [10]. Duman RS, Aghajanian GK. Neurobiology of major depression. *Biol Psychiatry*. 2012;71(7):410–416.
- [11]. Otte C, Gold SM, Penninx BW, et al. Stress and depression. *Nat Rev Neurosci*. 2016;17(7):434–448.
- [12]. Nestler EJ, Hyman SE. Animal models of depression. *Biol Psychiatry*. 2010;65(3):233–239.
- [13]. Wong ML, Licinio J. Research on depression. *J Affect Disord*. 2001;63(1–3):103–116.
- [14]. World Health Organization. Social isolation and health risks. *WHO Bulletin*; 2020.
- [15]. Holt-Lunstad J, Smith TB, Baker M, Harris T, Stephenson D. Loneliness and mortality risk. *Perspect Psychol Sci*. 2015;10(2):227–237.
- [16]. Cacioppo JT, Cacioppo S. Loneliness in the modern age. *Lancet*. 2018;391(10113):2590–2592.
- [17]. Matthews T, Danese A. Social isolation, loneliness, and mental health. *Trends Cogn Sci*. 2020;24(12):1103–1115.
- [18]. Santini ZI, Jose PE, Cornwell EY, et al. Social disconnectedness and depression. *J Gerontol B*. 2020;75(2):367–377.
- [19]. Leigh-Hunt N, Bagguley D, Bash K, et al. Social isolation and public health. *Public Health*. 2017;152:157–171.
- [20]. Murthy RS. Loneliness as a public health issue. *Indian J Psychiatry*. 2020;62(4):343–348.
- [21]. Kendler KS. Major depression: epidemiological perspectives. *Am J Psychiatry*. 2016;173(1):1–10.
- [22]. Caspi A, Sugden K, Moffitt TE, et al. Serotonin gene and depression. *Science*. 2003;301(5631):386–389.
- [23]. Belmaker RH, Agam G. Major depressive disorder. *N Engl J Med*. 2008;358(1):55–68.
- [24]. Bauer M, Severus E, Kohler S, et al. Pharmacological treatment of unipolar depression. *Int J Psychiatry Clin Pract*. 2013;17(1):3–11.
- [25]. Stahl SM. Mechanism of action of antidepressants. *CNS Spectr*. 2017;22(4):1–10.
- [26]. Delgado PL. Role of serotonin in depression. *J Clin Psychiatry*. 2000;61(Suppl 6):7–14.
- [27]. Trivedi MH, Daly EJ. Treatment-resistant depression. *N Engl J Med*. 2019;380(3):1139–1148.
- [28]. Andrade C. Ketamine for depression. *J Clin Psychiatry*. 2017;78(4):e415–e419.
- [29]. McIntyre RS, Carvalho AF. Adjunct therapies in depression. *CNS Drugs*. 2014;28(2):121–129.
- [30]. Cuijpers P, van Straten A, Warmerdam L. Psychotherapy vs pharmacotherapy. *Depress Anxiety*. 2009;26(2):106–115.